ustekinumab
janssen
['ustekinumab']
rates of key safety events, such as malignancies and major adverse cardiovascular events, were comparable among patients receiving placebo and #ustekinumab. #ddw2023 
HCPLive Rheumatology provides clinically impactful news and updates for HCPs treating rheumatic disease.